UofLRBLOperations,WorkforceDevelopment and PandemicPreparednessResearch
Project Number1UC7AI180309-01
Contact PI/Project LeaderPALMER, KENNETH E
Awardee OrganizationUNIVERSITY OF LOUISVILLE
Description
Abstract Text
SUMMARY (OVERALL):
The University of Louisville Regional Biocontainment Laboratory (RBL) is operated by the University Center for
Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM). The RBL is a regional resource
that facilitates translational research to develop diagnostics, prognostics, therapeutics and vaccines to mitigate
biodefense and emerging infectious disease threats. Our Center operates the only BSL-3 and ABSL-3 facilities
currently operating in the Commonwealth of Kentucky. The CPM mandate is to prepare for and respond to public
health emergencies, such as the COVID-19 pandemic.
The broad, long-range objectives and goals of the University of Louisville (UofL) CPM RBL are:
1. To offer state-of-the-art research services to the regional and national biomedical research community to
learn from past pandemics and biological warfare experiences and effectively predict and mitigate future
emerging infectious disease threats.
2. To manage, maintain and operate the UofLRBL to serve the national and regional need for biocontainment
facilities suitable for research on Risk Group 3 pathogens and other biothreats.
3. To follow a philosophy of continuous improvement in BSL-3 and ABSL-3 work practices and to ensure that
all personnel who need to access BSL-3 and ABSL-3 containment laboratories are appropriately trained and
prepared to serve the national and regional need for biocontainment research professionals.
To achieve these aims we propose to establish three collaborative Cores. The Facilities Management
Maintenance and Operations Core (FMMO Core) is responsible for ensuring that the facility is always available
to meet the research and emergency preparedness mission of the RBL. The BSL-3 Practices and WorkforceDevelopment Core (BSL-3PWD Core) formalizes our mentor-mentee training plan to ensure our laboratory is
staffed with BSL-3 research professionals who are proficient at biocontainment research professionals. This core
responds to the reality that response to rapidly emerging public health emergencies like COVID-19 is limited by
the number of available BSL-3 trained and experienced research professionals. Our PandemicPreparedness
and Response Integrated Research Core (PaPR Core) responds to the substantially increased requests for our
BSL-3 research services by organizing an integrated full-service BSL-3 research support function to support
investigator needs. These cores will work in unison to achieve the CPM mission: to prepare for and respond to
public health emergencies like the COVID-19 pandemic.
Public Health Relevance Statement
NARRATIVE (OVERALL):
The University of Louisville Regional Biocontainment Laboratory (RBL) is a regional resource that facilitates
translational research to develop diagnostics, therapeutics and vaccines to mitigate biodefense and emerging
infectious disease threats. We propose to establish three cores that will work in unison to achieve the RBL
mission to prepare and respond to public health emergencies like pandemics. The cores will be responsible for
facility management and operations; for training laboratory workers in safe BSL-3 work practices; and for
operating a full-service research support function for scientists who need to use the RBL.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AttentionBiological WarfareBiomedical ResearchBiotechnologyCOVID-19COVID-19 pandemicCOVID-19 patientChinaClinical TrialsCommunitiesContainmentCreativenessCrownsDedicationsDiagnosticDisease OutbreaksEconomicsEmerging Communicable DiseasesEnsureFederal GovernmentFunding OpportunitiesFutureGoalsHealth Services ResearchHealth care facilityHospitalsHourHuman ResourcesIndustryInfectionInstitutionInternationalInvestigational New Drug ApplicationKentuckyLaboratoriesLeadershipLearningMaintenanceManaged CareMedicineMentorsMissionModelingNational Center for Advancing Translational SciencesNational Institute of Diabetes and Digestive and Kidney DiseasesNosePatientsPhilosophyPlayPublic HealthResearchResearch PersonnelResearch SupportResourcesRestReverse Transcriptase Polymerase Chain ReactionRiskRoleScientistSerology testServicesSystemTalentsTechniquesTestingTherapeuticTrainingTranslational ResearchUnited States National Institutes of HealthUniversitiesUniversity resourcesVaccinesWorkWorkforceDevelopmentbiocontainment facilitybiodefensebiothreatcohortemergency preparednessexperienceimprovedlaboratory experiencemedical countermeasuremetropolitannovelnovel coronavirusoperationpandemic diseasepandemicpreparednesspandemic responsepathogenprevious pandemicprognosticprophylacticpublic health emergencyrecruitresponseservice organizationskillswastewater surveillance
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
057588857
UEI
E1KJM4T54MK6
Project Start Date
18-August-2023
Project End Date
31-July-2028
Budget Start Date
18-August-2023
Budget End Date
31-July-2024
Project Funding Information for 2023
Total Funding
$2,935,664
Direct Costs
$1,957,084
Indirect Costs
$978,580
Year
Funding IC
FY Total Cost by IC
2023
National Institute of Allergy and Infectious Diseases
$2,935,664
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1UC7AI180309-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1UC7AI180309-01
Patents
No Patents information available for 1UC7AI180309-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1UC7AI180309-01
Clinical Studies
No Clinical Studies information available for 1UC7AI180309-01
News and More
Related News Releases
No news release information available for 1UC7AI180309-01
History
No Historical information available for 1UC7AI180309-01
Similar Projects
No Similar Projects information available for 1UC7AI180309-01